November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
3 citations
,
July 2022 in “BMC chemistry” The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.
January 2016 in “Reactions Weekly” A girl's hair loss from a pharmacy error improved after getting the right medicine.
Telogen Effluvium causes increased hair shedding and can be challenging to diagnose and treat.
14 citations
,
November 1987 in “Journal of The American Academy of Dermatology” A woman developed a severe skin reaction called toxic epidermal necrolysis after taking the antibiotic cephalexin.
188 citations
,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
January 2026 in “Internal Medicine Journal” Direct-to-consumer telemedicine in Australia needs formal evaluation for safety and quality.
August 2019 in “DOAJ (DOAJ: Directory of Open Access Journals)” Telogen effluvium is a common, distressing condition causing excessive hair shedding and has significant psychological effects on patients.
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
December 2024 in “Ukrainian Journal of Dermatology Venerology Cosmetology” "Alpenta" effectively reduces hair loss and improves hair growth in women with telogen effluvium.
3 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
December 2022 in “Journal of The European Academy of Dermatology and Venereology” The 7.1% withdrawal rate was in the oral finasteride group, not the topical one.
February 2010 in “Journal of The American Academy of Dermatology” Posaconazole is a promising new treatment for toenail fungus.
January 2025 in “AAPS PharmSciTech” Transethosomes improve drug delivery through the skin and show promise for treating various conditions.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
August 2002 in “Inpharma Weekly” 5 citations
,
May 2017 in “Journal of dermatological science” The combined treatment effectively managed severe skin issues in Olmsted syndrome.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
41 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
6 citations
,
June 2021 in “EClinicalMedicine” ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
January 2023 in “DIGITAL HEALTH” Most men using teledermatology for hair loss treatment saw improved hair and self-esteem, with some experiencing side effects.
July 2006 in “Inpharma Weekly”
April 2022 in “Jurnal Ilmiah Kesehatan Media Husada” Telogen effluvium is a common, reversible hair loss condition treatable with patient education and sometimes Minoxidil.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.